Latest Conference Articles

Stay up to date on the latest oncology and nursing conferences.

Bone-Protecting Agents Reduce Fracture Risk During Prostate Cancer Treatment

Bone-Protecting Agents Reduce Fracture Risk During Prostate Cancer Treatment

June 9th 2021, 2:00pm

Men with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer who are being treated with radium-223 (Xofigo) plus enzalutamide (Xtandi) can reduce their risk of fractures with the use of bone-protecting agents.

Second-Generation CAR T-Cell Therapy Is ‘Highly Promising’ in Relapsed/Refractory B-NHL

Second-Generation CAR T-Cell Therapy Is ‘Highly Promising’ in Relapsed/Refractory B-NHL

June 8th 2021, 6:30pm

ASCO Annual Meeting

The second-generation 4-1BB bi-specific CAR T-cell therapy was efficacious and safe in treating patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

Sacituzumab Govitecan Beats All Chemo Regimens in TNBC Treatment

Sacituzumab Govitecan Beats All Chemo Regimens in TNBC Treatment

June 8th 2021, 1:31pm

Sacituzumab govitecan, an antibody drug conjugate, maintained survival and response benefits over chemotherapy regimens.

Acalabrutinib: Same Survival Rates, But Better Tolerated Than Ibrutinib in CLL Treatment

Acalabrutinib: Same Survival Rates, But Better Tolerated Than Ibrutinib in CLL Treatment

June 7th 2021, 5:51pm

ASCO Annual Meeting

Survival rates were similar between the 2 drugs, but acalabrutinib had fewer adverse events.

Melanoma Outcomes Are Improved With Nivolumab Alone or With Ipilimumab

Melanoma Outcomes Are Improved With Nivolumab Alone or With Ipilimumab

June 7th 2021, 1:56pm

ASCO Annual Meeting

Nivolumab with or without ipilimumab improved survival over ipilimumab alone in patients with previously untreated advanced melanoma.

Retevmo Shows Improvement for Previously Treated Patients With Non-Small Cell Lung Cancer

Retevmo Shows Improvement for Previously Treated Patients With Non-Small Cell Lung Cancer

June 6th 2021, 7:00pm

ASCO Annual Meeting

Previously treated patients with non-small cell lung cancer tended to have better responses with Retevmo than they did with prior treatments.

Adjuvant Chemo Does Not Improve Survival in Locally Advanced Cervical Cancer

Adjuvant Chemo Does Not Improve Survival in Locally Advanced Cervical Cancer

June 5th 2021, 3:30pm

ASCO Annual Meeting

Adjuvant carboplatin and paclitaxel after standard cisplatin-based chemoradiation did not demonstrate improved overall survival or progression-free survival in patients with locally advanced cervical cancer.

 Pralsetinib Is Tolerable, Durable in RET Fusion+ NSCLC

Pralsetinib Is Tolerable, Durable in RET Fusion+ NSCLC

June 4th 2021, 5:21pm

ASCO Annual Meeting

Pralsetinib elicited promising responses and tolerability in patients with RET fusion-positive non-small cell lung cancer (NSCLC), including those who were not eligible for platinum-based therapy.

Olaparib Is Beneficial 1 Year After Standard of Care Therapies in BRCA, High-Risk, Early HER2- Breast Cancer

Olaparib Is Beneficial 1 Year After Standard of Care Therapies in BRCA, High-Risk, Early HER2- Breast Cancer

June 4th 2021, 2:16pm

ASCO Annual Meeting

Patients with BRCA1/2-mutant, early HER2-negative breast cancer at a high risk of recurrence saw a clinically meaningful benefit 1 year after standard of care when treated with olaparib.

Restrictive Medicaid Eligibility May Negatively Impact Cancer Survival

Restrictive Medicaid Eligibility May Negatively Impact Cancer Survival

May 21st 2021, 1:20pm

ASCO Annual Meeting

States without Medicaid expansion tended to have poorer cancer outcomes than states with higher income limits on eligibility, according to recent research.